Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Gross Margin (2019 - 2025)

Bioadaptives' Gross Margin history spans 7 years, with the latest figure at 83.14% for Q3 2025.

  • For Q3 2025, Gross Margin changed N/A year-over-year to 83.14%; the TTM value through Sep 2025 reached 62.59%, down 1184.0%, while the annual FY2024 figure was 31.81%, 607.0% down from the prior year.
  • Gross Margin for Q3 2025 was 83.14% at Bioadaptives, up from 33.02% in the prior quarter.
  • Across five years, Gross Margin topped out at 83.14% in Q3 2025 and bottomed at 25.85% in Q4 2022.
  • The 5-year median for Gross Margin is 52.53% (2021), against an average of 48.03%.
  • The largest annual shift saw Gross Margin surged 5107bps in 2021 before it crashed -3053bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 29.65% in 2021, then dropped by -13bps to 25.85% in 2022, then soared by 45bps to 37.48% in 2023, then surged by 70bps to 63.56% in 2024, then soared by 31bps to 83.14% in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Gross Margin are 83.14% (Q3 2025), 33.02% (Q2 2025), and 63.56% (Q2 2024).